Eubiologics Co., Ltd. (206650)
KRX SM KRX SM Primary Summary
Eubiologics Co., Ltd. (206650) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Eubiologics Co., Ltd. ever had a stock split?
Eubiologics Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Yeong-Ok Baik CEO | KRX SM Exchange | KR7206650004 ISIN |
| KR Country | - Employees | - Last Dividend | 12 Nov 2020 Last Split | - IPO Date |
Overview
EuBiologics Co., Ltd., established in 2010 and headquartered in Seoul, South Korea, is a pioneering biopharmaceutical entity focused on the development and provision of vaccines targeting epidemic diseases prevalent within South Korea and beyond. The firm's strategic orientation embraces not just the creation and distribution of preventive healthcare solutions like vaccines, but it extends to offering comprehensive Contract Manufacturing Organization (CMO) and Contract Research and Manufacturing Services (CRMO) services. These services span across various critical phases of vaccine development and production, including drug product production, cell bank creation, drug substance production, cell line development, Good Manufacturing Practice (GMP) production, validation processes, and regulatory support. EuBiologics stands as a key player in the biopharmaceutical sector, possessing extensive facilities tailored for the production of protein-based therapeutics and antibodies.
Products and Services
1. Euvichol Plus: An oral vaccine designed for the prevention of cholera, demonstrating EuBiologics' commitment to combating waterborne diseases with far-reaching impacts on public health.
2. rCRM197: A diphtheria toxoid vaccine, highlighting the company's efforts in creating solutions for the prevention of diphtheria, a serious bacterial infection affecting the mucous membranes of the throat and nose.
3. EcML: This product represents EuBiologics' innovative approach towards vaccine development, focusing on cell membrane technology.
4. COVID-19 Diagnostic Kits: In response to the global pandemic, EuBiologics has expanded its portfolio to include diagnostic kits aimed at the detection of COVID-19, showcasing the company's flexibility and rapid response to emerging health crises.
5. CMO Services: EuBiologics offers a wide range of Contract Manufacturing Organization services that include:
- Drug Product Production: Specializing in the formulation and processing of drug products.
- Cell Bank Production: Providing services for the creation and maintenance of cell banks, essential for biological research and production.
- Drug Substance Production: Focused on the production of the active pharmaceutical ingredients (APIs).
6. CRMO Services: Complementing its CMO offerings, the company's Contract Research and Manufacturing Services include:
- Cell Line Development: Developing and optimizing cell lines for vaccine and therapeutic protein production.
- GMP Production: Manufacturing drugs under Good Manufacturing Practice conditions to ensure quality and safety.
- Validation: Conducting studies to confirm the reproducibility of the production process.
- Regulatory Support: Offering assistance in navigating the complex regulatory environment for drugs and vaccines.
7. Contract Testing Services: EuBiologics provides a comprehensive range of testing services, critical for ensuring the safety, efficacy, and quality of pharmaceutical products. These services cover lot release testing, stability testing, raw material testing, and method validation testing, further underlining the company's versatility and commitment to supporting the lifecycle of biopharmaceutical products.
